男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
     
 
Home> News
China and Cuba co-develop new anti-cancer vaccine
(chinadaily.com.cn)
Updated: 2012-03-29
 

Jointly developed by China and Cuba, a new kind of vaccine used to treat non-small-cell lung cancer (NSCLC) has obtained the approval of China's State Food and Drug Administration. It is about to conduct clinical tests at the Chinese Academy of Medical Sciences (CAMS).

The news was released at the China-Cuba Biopharmaceutical Achievement Analysis and Prospect Conference, held by the Biotech Pharmaceuticals Co Ltd.

Dr. Agustín Lage Dávila is the director of the Center of Molecular Immunology and is a renowned biotechnologist in Cuba. He said, "After diagnosis, the development of the tumor will usually disappear and recur with therapy progress."

Dr. Lage said Cimavax, the new vaccine that was jointly developed by Cuba and Biotech, is a conjugated vaccine that recombines the epidermal growth factor (EGF). As a therapeutic vaccine, it directs the EGF required by tumor expansion and prevents the further proliferation of tumor tissues. It thereby keeps the tumor at a stable level and transforms the cancer into a chronic disease, which greatly extends the survival time of the patient.

The clinical trial of this therapeutic vaccine has been conducted in Cuba with local drug registration. Meanwhile, many countries and regions in Europe and Asia have launched the registration trials of the vaccine and have gained positive preliminary results. At present, the vaccine is being converted into product for China.

The Cancer Hospital of CAMS is the partner of the Phase I clinical trial of the project. Vice-president professor, Shi Yuankai, confirmed that the new vaccine will first enter the Phase I clinical trial in the hospital starting in March. Dr. Lage predicted that after two years of clinical trials, the new anticancer vaccine will be put into the market.

As the largest project of the China-Cuba biological cooperation, Biotech has acquired spectacular results in the field of biopharmaceutical anticancer. During its development in the past decade, Biotech has made remarkable achievements in tumor research and treatment and created the first domestic antibody humanization technology platform at a world leading level.

The company has also designed and constructed China's first full-automatic and large-scale mammalian cell culture production line, and researched and developed Nimotuzomab - the first humanized monoclonal antibody of gene recombination for malignant tumor treatment.

Edited by Chen Zhilin and Rakhee M

 

Zhang Hui

Zhang Hui, Board Chairman and Chief Executive Officer of Beijing Innofidei.

 

Yu Zhenhua

Yu Zhenhua, Board Chairman of Beijing Prudent Energy Inc.

 

Deng Zhonghan

Deng Zhonghan, Board Chairman of Vimicro.

 
 

Zhongguancun Science Park

主站蜘蛛池模板: 隆昌县| 茶陵县| 五家渠市| 贺州市| 温泉县| 武乡县| 永平县| 霞浦县| 孟连| 黑龙江省| 怀安县| 宜宾市| 太仓市| 象山县| 亳州市| 巢湖市| 耒阳市| 烟台市| 金坛市| 平顺县| 原阳县| 吉林省| 安康市| 青神县| 大港区| 浏阳市| 寿阳县| 双辽市| 谷城县| 科技| 宁陕县| 双峰县| 海口市| 中阳县| 青海省| 红河县| 淅川县| 贵州省| 东港市| 雷山县| 江山市| 汕头市| 徐闻县| 乌恰县| 揭东县| 司法| 子洲县| 平阳县| 平定县| 库伦旗| 古交市| 临桂县| 林西县| 天柱县| 泗阳县| 宝鸡市| 磐石市| 东兴市| 鄂托克旗| 澄城县| 邯郸市| 化德县| 响水县| 潍坊市| 普洱| 福建省| 清苑县| 泸州市| 曲水县| 山东省| 尚义县| 和平县| 陇川县| 临猗县| 台山市| 五台县| 永丰县| 武冈市| 军事| 萨嘎县| 郯城县| 布拖县|